Key Points
- Director David Pelizzon sold 22,500 OrthoPediatrics shares at an average price of $23.35, generating $525,375. He retained 6.5 million shares, with the sale reducing his ownership by 0.34%.
- OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst estimates of $68.21 million in revenue and a $0.30 per-share loss.
- Analyst sentiment remains favorable, with nine Buy ratings, one Hold and one Sell; the stock has a “Moderate Buy” consensus rating and a $26.44 average price target versus its reported $22.41 opening price.
OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 22,500 shares of OrthoPediatrics stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $23.35, for a total transaction of $525,375.00. Following the sale, the director owned 6,504,133 shares in the company, valued at approximately $151,871,505.55. This represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
OrthoPediatrics Stock Performance
Shares of KIDS opened at $22.41 on Friday. The firm has a market capitalization of $585.13 million, a PE ratio of -13.34 and a beta of 0.99. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average price of $21.78 and a 200 day moving average price of $18.87. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, sell-side analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.
Institutional Trading of OrthoPediatrics
Several institutional investors and hedge funds have recently bought and sold shares of KIDS. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock worth $26,000 after buying an additional 1,139 shares during the period. Legal & General Group Plc acquired a new stake in shares of OrthoPediatrics during the second quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock valued at $46,000 after acquiring an additional 2,561 shares in the last quarter. Caption Management LLC purchased a new stake in shares of OrthoPediatrics in the third quarter valued at $54,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,235 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on KIDS. TD Cowen reaffirmed a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Weiss Ratings upgraded OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 5th. Needham & Company LLC raised their target price on OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. BTIG Research boosted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Finally, Piper Sandler restated an "overweight" rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $26.44.
Check Out Our Latest Stock Report on OrthoPediatrics
OrthoPediatrics Company Profile
(
Get Free Report)
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
